| Year |
Citation |
Score |
| 2023 |
Stueven NA, Beauvais DM, Hu R, Kimple RJ, Rapraeger AC. Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTN. Cancer Research Communications. 3: 97-108. PMID 36968227 DOI: 10.1158/2767-9764.CRC-22-0274 |
0.665 |
|
| 2022 |
Beauvais DM, Nelson SE, Adams KM, Stueven NA, Jung O, Rapraeger AC. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression. The Journal of Biological Chemistry. 102029. PMID 35569509 DOI: 10.1016/j.jbc.2022.102029 |
0.643 |
|
| 2019 |
Jung O, Beauvais DM, Adams KM, Rapraeger AC. VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. Journal of Cell Science. PMID 31562188 DOI: 10.1242/Jcs.232645 |
0.695 |
|
| 2016 |
Beauvais DM, Jung O, Yang Y, Sanderson RD, Rapraeger AC. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Research. PMID 27364558 DOI: 10.1158/0008-5472.Can-16-0232 |
0.686 |
|
| 2014 |
Wang H, Jin H, Beauvais DM, Rapraeger AC. Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with α6β4 integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival. The Journal of Biological Chemistry. 289: 30318-32. PMID 25202019 DOI: 10.1074/Jbc.M114.586438 |
0.691 |
|
| 2013 |
Rapraeger AC, Ell BJ, Roy M, Li X, Morrison OR, Thomas GM, Beauvais DM. Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. The Febs Journal. 280: 2194-206. PMID 23331867 DOI: 10.1111/Febs.12134 |
0.667 |
|
| 2010 |
Beauvais DM, Rapraeger AC. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. Journal of Cell Science. 123: 3796-807. PMID 20971705 DOI: 10.1242/Jcs.067645 |
0.732 |
|
| 2009 |
Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. The Journal of Experimental Medicine. 206: 691-705. PMID 19255147 DOI: 10.1084/Jem.20081278 |
0.744 |
|
| 2009 |
Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates αvβ3and αvβ5integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor The Journal of Cell Biology. 184: i12-i12. DOI: 10.1083/JCB1845OIA12 |
0.63 |
|
| 2008 |
Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Synstatin, a Sdc1 peptide, blocks αvβ3-dependent angiogenesis Matrix Biology. 27: 12. DOI: 10.1016/J.Matbio.2008.09.229 |
0.616 |
|
| 2006 |
McQuade KJ, Beauvais DM, Burbach BJ, Rapraeger AC. Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. Journal of Cell Science. 119: 2445-56. PMID 16720645 DOI: 10.1242/Jcs.02970 |
0.689 |
|
| 2006 |
BEAUVAIS D, MCWHORTER A, ELL B, RAPRAEGER A. Syndecan_1 regulates β3 and β5 integrin tumor_promoting activity Matrix Biology. 25: S42-S42. DOI: 10.1016/J.Matbio.2006.08.116 |
0.603 |
|
| 2004 |
Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. The Journal of Cell Biology. 167: 171-81. PMID 15479743 DOI: 10.1083/Jcb.200404171 |
0.733 |
|
| 2004 |
Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reproductive Biology and Endocrinology : Rb&E. 2: 3. PMID 14711376 DOI: 10.1186/1477-7827-2-3 |
0.689 |
|
| 2003 |
Beauvais DM, Rapraeger AC. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Experimental Cell Research. 286: 219-32. PMID 12749851 DOI: 10.1016/S0014-4827(03)00126-5 |
0.702 |
|
| Show low-probability matches. |